[go: up one dir, main page]

WO1996013594A8 - Fragments d'anticorps a specificite tumorale, proteines de fusion, et leurs utilisations - Google Patents

Fragments d'anticorps a specificite tumorale, proteines de fusion, et leurs utilisations

Info

Publication number
WO1996013594A8
WO1996013594A8 PCT/US1995/013811 US9513811W WO9613594A8 WO 1996013594 A8 WO1996013594 A8 WO 1996013594A8 US 9513811 W US9513811 W US 9513811W WO 9613594 A8 WO9613594 A8 WO 9613594A8
Authority
WO
WIPO (PCT)
Prior art keywords
provides
fusion proteins
lewisy
antibodies
regions
Prior art date
Application number
PCT/US1995/013811
Other languages
English (en)
Other versions
WO1996013594A1 (fr
Inventor
Ira Pastan
Itai Benhar
Eduardo A Padlan
Sun-Hee Jung
Byungkook Lee
Mark Willingham
David Fitzgerald
Ulrich Brinkmann
Lee Pai
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/331,398 external-priority patent/US5608039A/en
Priority claimed from US08/331,397 external-priority patent/US5981726A/en
Priority claimed from US08/331,396 external-priority patent/US5889157A/en
Application filed by Us Health filed Critical Us Health
Priority to JP8514718A priority Critical patent/JPH10508202A/ja
Priority to EP95939599A priority patent/EP0796334A1/fr
Priority to AU41355/96A priority patent/AU717611B2/en
Publication of WO1996013594A1 publication Critical patent/WO1996013594A1/fr
Publication of WO1996013594A8 publication Critical patent/WO1996013594A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cette invention se rapporte à des anticorps monochaînes recombinés, qui sont capables de se fixer spécifiquement à un antigène d'hydrate de carbone apparenté aux antigènes de LewisY, ainsi qu'à des protéines de fusion comprenant ces anticorps. Cette invention concerne plus particulièrement les régions Fv monochaîne (scFv) des anticorps monoclonaux B1, B3 et B5, les régions Fv monochaîne humanisées de ces anticorps B1, B3 et B5, ainsi que des protéines de fusion comprenant ces régions scFv. L'invention présente également un certain nombre de mutations stabilisantes de l'anticorps monoclonal B3 se fixant aux antigènes de LewisY. Cette invention concerne en outre des procédés permettant de détecter des cellules portant un antigène de LewisY chez un patient, ainsi que des procédés pour détruire des cellules portant un antigène de LewisY chez un patient ou pour empêcher la croissance de telles cellules. Cette invention se rapporte également à un procédé permettant d'améliorer l'affinité de fixation d'anticorps auxquels ilmanque une sérine à la position 95 de la région V¿H?, ce procédé impliquant la mutation de la position 95 sur une sérine.
PCT/US1995/013811 1994-10-28 1995-10-26 Fragments d'anticorps a specificite tumorale, proteines de fusion, et leurs utilisations WO1996013594A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP8514718A JPH10508202A (ja) 1994-10-28 1995-10-26 腫瘍特異性抗体断片、融合タンパク質、およびそれらの使用
EP95939599A EP0796334A1 (fr) 1994-10-28 1995-10-26 Fragments d'anticorps a specificite tumorale, proteines de fusion, et leurs utilisations
AU41355/96A AU717611B2 (en) 1994-10-28 1995-10-26 Tumor-specific antibody fragments, fusion proteins, and uses thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US08/331,398 US5608039A (en) 1990-10-12 1994-10-28 Single chain B3 antibody fusion proteins and their uses
US08/331,398 1994-10-28
US08/331,397 US5981726A (en) 1990-10-12 1994-10-28 Chimeric and mutationally stabilized tumor-specific B1, B3 and B5 antibody fragments; immunotoxic fusion proteins; and uses thereof
US08/331,396 US5889157A (en) 1990-10-12 1994-10-28 Humanized B3 antibody fragments, fusion proteins, and uses thereof
US08/331,396 1994-10-28
US08/331,397 1994-10-28

Publications (2)

Publication Number Publication Date
WO1996013594A1 WO1996013594A1 (fr) 1996-05-09
WO1996013594A8 true WO1996013594A8 (fr) 2000-04-06

Family

ID=27406791

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/013811 WO1996013594A1 (fr) 1994-10-28 1995-10-26 Fragments d'anticorps a specificite tumorale, proteines de fusion, et leurs utilisations

Country Status (4)

Country Link
EP (1) EP0796334A1 (fr)
AU (1) AU717611B2 (fr)
CA (1) CA2203236A1 (fr)
WO (1) WO1996013594A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
WO2000026394A1 (fr) * 1998-10-31 2000-05-11 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Variants de l'anticorps monoclonal anti-carcinome de type humain cc49
EP1434800B1 (fr) * 2001-09-14 2010-12-01 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Immunoglobuline dotee d'un squelette particulier ; methodes de fabrication et d'utilisation
CA2420494A1 (fr) * 2003-02-28 2004-08-28 Universite De Sherbrooke Fonction de l'antigene tumoral ca 125 et utilisations therapeutiques de celui-ci
WO2004003155A2 (fr) 2002-06-28 2004-01-08 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Les cc49, anti-tag-72 humanises servant au diagnostic et au traitement de tumeurs chez l'homme
CU23403A1 (es) 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
WO2005021594A2 (fr) 2003-08-29 2005-03-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Variants a peine immunogenes de l'anticorps humanise a greffe sdr cc49 et leur utilisation
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
GB201910899D0 (en) * 2019-07-31 2019-09-11 Scancell Ltd Binding members

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3512795B2 (ja) * 1991-09-30 2004-03-31 アメリカ合衆国 組換免疫毒素

Also Published As

Publication number Publication date
AU717611B2 (en) 2000-03-30
WO1996013594A1 (fr) 1996-05-09
AU4135596A (en) 1996-05-23
CA2203236A1 (fr) 1996-05-09
EP0796334A1 (fr) 1997-09-24

Similar Documents

Publication Publication Date Title
WO1997020575A8 (fr) Vecteurs adenoviraux cibles
WO1997025042A8 (fr) Utilisation d'un agoniste de ppar-alpha et de ppar-gamma dans le traitement du syndrome x
WO1997017980A8 (fr) Traitement de la cardiomyopathie par elimination des auto-anticorps
WO1996001622A8 (fr) Nouvelle preparation pharmaceutique a administration orale contenant un sel magnesien d'omeprazole
WO1996013594A8 (fr) Fragments d'anticorps a specificite tumorale, proteines de fusion, et leurs utilisations
US5965133A (en) Self-assembling multimeric nucleic acid constructs
Toggas et al. Central nervous system damage produced by expression of the HIV-1 coat protein gpl20 in transgenic mice
EP0367644B1 (fr) Séquence de nucléotides codant pour une proteine à activité uréasique
WO1997006318A8 (fr) Cloison insonorisante
Olsvik et al. Metal accumulation and metallothionein in two populations of brown trout, Salmo trutta, exposed to different natural water environments during a run-off episode
WO1998016421A8 (fr) Dispositif de lecture, detection, choix d'objectifs, communication et reponse base sur un aeronef
US20070218494A1 (en) Branched polymer lables as drag-tags in free solution electrophoresis
WO1998040762B1 (fr) Systeme telemetrique actif guide par image
WO2020014097A8 (fr) Réactifs et méthodes de traitement du cancer et de maladies auto-immunes
WO1994024204A3 (fr) Composition de materiau de revetement pour balle de golf
Rouault et al. Influence of altered transcription on the translational control of human ferritin expression.
RU2005141341A (ru) Полинуклеотид, родственный антигену стволовых клеток простаты (psca), и кодируемый им белок (пептид), гибридома и трансгенное животное для продуцирования антител, композиция для лечения, профилактики, диагностики и прогноза течения раковых заболеваний на их основе (варианты), способ определения их присутствия в исследуемом образце, способ генерации иммунного ответа, способ доставки цитотоксического или диагностического агента в клетку, способ ингибирования роста раковых клеток с их использованием
Sontheimer et al. Three novel functional variants of human U5 small nuclear RNA
Yamazoe et al. Sequential binding of SeqA protein to nascent DNA segments at replication forks in synchronized cultures of Escherichia coli
Lae et al. Clusterin is widely expressed in systemic anaplastic large cell lymphoma but fails to differentiate primary from secondary cutaneous anaplastic large cell lymphoma
WO1997020810A8 (fr) Procede de preparation de derives de 1-aryl-1-cyanocyclobutane
Redmond et al. A serine protease (CCP1) is sequestered in the cytoplasmic granules of cytotoxic T lymphocytes.
Baran et al. The modifier of Min 2 (Mom2) locus: embryonic lethality of a mutation in the Atp5a1 gene suggests a novel mechanism of polyp suppression
Navaglia et al. Helicobacter pylori cytotoxic genotype is associated with peptic ulcer and influences serology
WO2002037114A1 (fr) Agent permettant de detecter l'aptitude d'une tumeur cancereuse a se metastaser

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase in:

Ref country code: CA

Ref document number: 2203236

Kind code of ref document: A

Format of ref document f/p: F

Ref document number: 2203236

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995939599

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1995939599

Country of ref document: EP

AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 21/96 UNDER (30) REPLACE "28.10.95" BY "28.10.94"

WWW Wipo information: withdrawn in national office

Ref document number: 1995939599

Country of ref document: EP